文献速递肿瘤 PET/CT核素与放射性配体治疗

在接受放疗的食管癌患者中,非肿瘤受累食管晚期治疗PET的FDG摄取预后价值证据增加

Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-04-21

该回顾性评估纳入72例接受根治性放化疗的食管鳞状细胞癌患者,于放疗剂量40-50 Gy后行再分期FDG PET。结果显示,非肿瘤受累食管的∆SUVmax是总生存、局部控制、远处转移和治疗失败的预后因素,在多因素分析中为独立预后因素。

要点

  • 非肿瘤受累食管∆SUVmax是全部临床终点的预后因素。
  • 使用既往已发表截断值,∆SUVmax NTO为OS独立预后因素(HR=1.88,p=0.038)。
  • ∆SUVmax NTO为TF(HR=2.11,p=0.048)和DM(HR=3.02,p=0.047)独立预后因素。

核心结论

  • 食管癌患者治疗过程中非肿瘤受累食管的示踪剂摄取具有高度预后相关性,以∆SUVmax NTO测量的非肿瘤受累食管代谢活性是未来治疗个体化(即器官保留)的潜在候选指标。

研究设计与样本

  • 回顾性评估纳入72例接受根治性放化疗的食管鳞状细胞癌患者,所有患者于放疗剂量40-50 Gy后行再分期FDG PET。

主要发现

  • ∆SUVmax NTO和MTV是所有研究临床终点(OS、LC、DM、TF)的预后因素。
  • 纳入临床和PET肿瘤参数的多因素分析显示,∆SUVmax NTO是独立预后因素。
  • 使用既往已发表截断值的多因素分析显示,∆SUVmax NTO为OS独立预后因素(HR=1.88,p=0.038)。
  • ∆SUVmax NTO为TF独立预后因素(HR=2.11,p=0.048)。
  • ∆SUVmax NTO为DM独立预后因素(HR=3.02,p=0.047)。

关键数值与推荐

  • ∆SUVmax NTO对OS的HR=1.88(p=0.038)。
  • ∆SUVmax NTO对TF的HR=2.11(p=0.048)。
  • ∆SUVmax NTO对DM的HR=3.02(p=0.047)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 18F-FDG uptake in irradiated non-tumour-affected oesophagus (NTO) on restaging PET is a potential surrogate for the measurement of radiation-induced inflammation. Radiation-induced inflammation itself has been shown to be of high prognostic relevance in patients undergoing preoperative radiochemotherapy (RCT) for locally advanced oesophageal cancer. We assessed the prognostic relevance of FDG uptake in the NTO in an independent cohort of patients treated with definitive RCT. METHODS: This retrospective evaluation included 72 patients with oesophageal squamous cell carcinoma treated with definitive RCT with curative intent. All patients underwent pretreatment and restaging FDG PET after receiving a radiation dose of 40-50 Gy. Standardized uptake values (SUVmax/SUVmean), metabolic tumour volume (MTV) and relative changes from pretreatment to restaging PET (∆SUVmax/∆SUVmean) were determined within the tumour and NTO. Univariate Cox regression with respect to overall survival (OS), local control (LC), distant metastases (DM) and treatment failure (TF) was performed. Independence of parameters was tested by multivariate Cox regression. RESULTS: ∆SUVmax NTO and MTV were prognostic factors for all investigated clinical endpoints (OS, LC, DM, TF). Inclusion of clinical and PET tumour parameters in multivariate analysis showed that ∆SUVmax NTO was an independent prognostic factor. Furthermore, multivariate analysis of ∆SUVmax NTO using previously published cut-off values from preoperatively treated patients revealed that ∆SUVmax NTO was independent prognostic factor for OS (HR = 1.88, p = 0.038), TF (HR = 2.11, p = 0.048) and DM (HR = 3.02, p = 0.047). CONCLUSION: NTO-related tracer uptake during the course of treatment in patients with oesophageal carcinoma was shown to be of high prognostic relevance. Thus, metabolically activity of NTO measured in terms of ∆SUVmax NTO is a potential candidate for future treatment individualization (i.e. organ preservation).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li Y, Hofheinz F, Furth C, et al. Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2018. PMID: 29679113. doi:10.1007/s00259-018-3996-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。